In non-small cell lung cancer (NSCLC), PAK1 served as clinical biomarker and its level was elevated in NSCLC tissues and cells; also, overexpressed PAK1 reverted the inhibitory impact of miR-98 on growth and mobility of NSCLC cells [33]. Here, PAK1 is linked to non-small cell lung carcinoma.